Company intelligence / Profile preview

Beijing Kejing Biotechnology

Beijing, Beijing Shi, Chinalinkedin.com ↗

Ownership: Private
Development stage: Preclinical

Overview

All known pipeline assets are currently at the pre-clinical stage with no published clinical results as of June 2025. The company's lead asset targets mesothelin via a CAR-NK approach for solid tumors; another program targets acute myeloid leukemia using an undisclosed modality/platform. There is also an early-stage cardiovascular disease program under development.

Therapeutic areas: OncologyEndocrinologyCardiovascularHematology
Modalities: CAR-NK cell therapyNatural Killer Cell TherapiesCAR-T cell therapy
Industry: Biotech

Drug pipeline

1 asset

CCT-ANK-11

Unknown

Beyond the preview

Go deeper on Beijing Kejing Biotechnology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Beijing Kejing Biotechnology.

Explore the full profile